These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2611523)

  • 1. Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover.
    Rose S; Thomas K; Jenner P; Marsden CD
    Br J Pharmacol; 1989 Dec; 98 Suppl():816P. PubMed ID: 2611523
    [No Abstract]   [Full Text] [Related]  

  • 2. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease.
    Rocchitta G; Migheli R; Esposito G; Marchetti B; Desole MS; Miele E; Serra PA
    J Pineal Res; 2006 Apr; 40(3):204-13. PubMed ID: 16499555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease.
    Bartus RT; Emerich D; Snodgrass-Belt P; Fu K; Salzberg-Brenhouse H; Lafreniere D; Novak L; Lo ES; Cooper T; Basile AS
    J Pharmacol Exp Ther; 2004 Aug; 310(2):828-35. PubMed ID: 15039453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
    Ueda H; Sato K; Okumura F; Inoue A; Nakata Y; Ozaki N; Yue JL; Misu Y
    Biomed Pharmacother; 1995; 49(4):169-77. PubMed ID: 7669936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics.
    Juncos JL
    Neurol Clin; 1992 May; 10(2):487-509. PubMed ID: 1584186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
    Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
    Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mild postnatal hypoxia and L-dopa administration on dopamine concentration in striata of the newborn rat and long term sequelae on dopamine turnover.
    Lun A; Szuecz L; Gross J; Horvath G; Nagy I
    Biomed Biochim Acta; 1989; 48(2-3):S231-6. PubMed ID: 2730615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
    Indo T
    Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
    [No Abstract]   [Full Text] [Related]  

  • 16. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Reches A; Fahn S
    Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic intermittent L-DOPA treatment induces changes in dopamine release.
    Lundblad M; af Bjerkén S; Cenci MA; Pomerleau F; Gerhardt GA; Strömberg I
    J Neurochem; 2009 Feb; 108(4):998-1008. PubMed ID: 19196428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catechol-O-methyltransferase and Parkinson's disease.
    Reches A; Fahn S
    Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.